Lupin jumps after its arm incorporates wholly owned subsidiary in New Zealand
Lupin is currently trading at Rs. 2062.00, up by 69.30 points or 3.48% from its previous closing of Rs. 1992.70 on the BSE.
The scrip opened at Rs. 2014.00 and has touched a high and low of Rs. 2066.30 and Rs. 2004.00 respectively. So far 72851 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2066.30 on 08-Aug-2024 and a 52 week low of Rs. 1061.25 on 21-Aug-2023.
Last one week high and low of the scrip stood at Rs. 2066.30 and Rs. 1901.45 respectively. The current market cap of the company is Rs. 93802.55 crore.
The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 46.10% and 6.92% respectively.
Lupin’s wholly owned subsidiary -- Generic Health, Australia has incorporated wholly owned subsidiary namely Lupin NZ, New Zealand. Lupin NZ will be engaged in the business of pharmaceuticals and pharmaceutical devices in New Zealand. Lupin NZ was incorporated under Certificate of Incorporation dated August 8, 2024, issued by the Registrar of Companies New Zealand under the Companies Act 1993.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
